Onsdag 28 Oktober | 17:16:20 Europe / Stockholm
Est. tid*
2027-08-25 08:30 Kvartalsrapport 2027-Q2
2027-05-12 08:30 Kvartalsrapport 2027-Q1
2027-02-10 10:30 Bokslutskommuniké 2026
2026-11-11 08:30 Kvartalsrapport 2026-Q3
2026-10-07 - Extra Bolagsstämma 2027
2026-08-26 - Kvartalsrapport 2026-Q2
2026-05-28 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2026-05-27 - Årsstämma
2026-05-25 - Årsstämma
2026-05-13 - Kvartalsrapport 2026-Q1
2026-02-26 - Extra Bolagsstämma 2026
2026-02-11 - Bokslutskommuniké 2025
2025-11-12 - Kvartalsrapport 2025-Q3
2025-08-27 - Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2025-05-28 - Årsstämma
2025-05-20 - Kvartalsrapport 2025-Q1
2025-03-21 - Extra Bolagsstämma 2025
2025-02-12 - Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-07-30 - Split QLIFE 2000:1
2024-05-28 - Kvartalsrapport 2024-Q1
2024-05-08 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2024-05-07 - Årsstämma
2024-02-08 - Bokslutskommuniké 2023
2024-01-16 - Extra Bolagsstämma 2023
2023-11-13 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-26 - Kvartalsrapport 2023-Q1
2023-05-05 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2023-05-04 - Årsstämma
2023-03-24 - Extra Bolagsstämma 2022
2023-02-16 - Bokslutskommuniké 2022
2022-11-25 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-08 - Kvartalsrapport 2021-Q3
2021-08-16 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-19 - Extra Bolagsstämma 2020
2020-11-18 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-05-22 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 - Årsstämma
2020-05-20 - Kvartalsrapport 2020-Q1
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret beläget i Helsingborg.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Qlife Holding AB: Qlife fully secures ongoing rights issue with top guarantee commitments

2023-04-13 09:50:29

Qlife Holding AB ("Qlife" or the "Company") has secured a top guarantee syndicate, in addition to the previously announced guarantee syndicate, in the ongoing rights issue of units which was announced through a press release on 16 February 2023 (the "Rights Issue"). The top guarantee syndicate amounts to approximately SEK 16.6 million, which corresponds to approximately 28.7 percent of the Rights Issue. Consequently, the Rights Issue is secured to 100 percent through the previously announced subscription undertakings and guarantee commitments and the top guarantee syndicate.

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.

In addition to the previously announced guarantee commitments, Qlife has secured a top guarantee syndicate in the ongoing Rights Issue, amounting to approximately SEK 16.6 million, corresponding to approximately 28.7 percent of the Rights Issue. Consequently, the Rights Issue is secured to 100 percent through the earlier announced subscription undertakings and guarantee commitments, and the top guarantee syndicate.

A guarantee fee will be paid to the top guarantors, based on current market conditions, of twenty (20) percent of the guaranteed and allotted amount. Twelve (12) percent of the fee will be paid in cash and eight (8) percent is to be offset against units to the same terms and conditions as for the other guarantee commitments entered into in connection with the Rights Issue. The guarantee compensation in newly issued units is to be effectuated by a directed issue of units, resolved by the board of directors based on the authorization granted by the extraordinary general meeting on 24 March 2023.

The guarantee commitments are not secured through bank guarantees, restricted funds, pledged assets or similar arrangements.

Due to the top guarantee commitments, Qlife will prepare a supplementary prospectus (the "Supplementary Prospectus") to the EU growth prospectus that was published on 6 April 2023 (the "Prospectus"). The Supplementary Prospectus, that will be published and announced through a separate press release once approved by the Swedish Financial Supervisory Authority, will include further information regarding the parties who have entered into top guarantee commitments.

Advisers

G&W Fondkommission acts as financial advisor and Setterwalls Advokatbyrå AB acts as legal advisor to Qlife in connection with the Rights Issue. Aqurat Fondkommission AB acts as issuing agent in connection with the Rights Issue.

This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 13-04-2023 09:50 CET.